Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Investor Presentation (April 2012)
23 slides from Immutep's investor presentation, Apr 16, 2012
Slide 1: The Cutting Edge in the Fight Against Cancer
Exhibit 99.1 The Cutting Edge in the Fight Against Cancer Investor Presentation April 2012 Martin Rogers (ASX:PRR, NASDAQ:PBMD) Chief Executive Officer
Slide 2: Important Notice
Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these
Slide 3: Prima BioMed: An Emerging Presence in Oncology
Prima BioMed: An Emerging Presence in Oncology • Prima BioMed is a biotechnology company focused on developing novel oncology therapies in the field of immunotherapy and immunology • Prima BioMed has a clear strategy to develop and commercialize therapeutic vaccine CVacTM in ovarian cancer with an o
Slide 4: Prima BioMed Investment Overview
Prima BioMed Investment Overview Leadership in emerging immunotherapy arena with CVac™ poised to commence pivotal clinical trials in the U.S., EU and Australia Focused on major markets with unmet medical needs and limited competition Broad intellectual property position Potential to leverage future
Slide 5: Prima BioMed: Introduction Leadership Team
Prima BioMed: Introduction Leadership Team Martin Rogers Managing Director and Chief Executive Officer Extensive business management experience & scientific background Dr. Neil Frazer Ian Bangs Mathew Lehman Chief Operating Officer Chief Medical Officer Chief Financial Officer & Experience in execut
Slide 6: CVac Targeting Ovarian Cancer
CVac™ Targeting Ovarian Cancer 6
Slide 7: CVac: Program Overview
CVac: Program Overview • CVac is an autologous, dendritic-cell based therapy or cancer vaccine • Proven technology with FDA approval of Provenge • Progressing clinical studies of the “first ovarian cancer therapeutic vaccine” • Upcoming pivotal (CANVAS) and ongoing Phase IIb trials to provide furthe
Slide 8: Program Overview (Con't.)
CVac: Program Overview (Con’t.) • CVac granted marketing & distribution approval in the Dubai Healthcare City – First sales expected in 2012 – Pilot scale commercialisation program – Generates revenue in growing Middle Eastern healthcare market • Manufacturing authorization in place and ready to go
Slide 9: Unique Mechanism of Action
CVac: Unique Mechanism of Action 9
Slide 10: Basis for Maintenance Therapy in Ovarian Cancer
CVac: Basis for Maintenance Therapy in Ovarian Cancer Unmet medical need in ovarian cancer 73,000 women diagnosed each year in the U.S., EU, Australian and Japan 318,000 women diagnosed globally Generally diagnosed at late stage Only 20-30% of patients with late stage disease survive 5 years Median
Slide 11: Evidence of Clinical Activity
CVac: Evidence of Clinical Activity • Phase Ib Study Design – 14 patients with terminal cancer (3-6 months life expectancy), broad range of adenocarcinomas including renal, breast, ovarian, fallopian tube, colon, lung & esophageal – Objectives: • Primary endpoint: safety and assess toxicity • Second
Slide 12: Ovarian Tumours Respond to Therapy with CA125 Reduction
CVac: Ovarian Tumours Respond to Therapy with CA125 Reduction • Phase IIa Study Design(n=28) – Patients received 3 CVac injections over 10 weeks, followed by 4 injections at 10 week intervals • 21 evaluable with incurable ovarian cancer • rising CA125 levels at least 25% over baseline within 28 days
Slide 13: Treating Stage III Ovarian Cancer Patient
Treating Stage III Ovarian Cancer Patient • Incurable recurrent disease, diagnosed by elevated CA125 marker • Low 5 year survival rate and late stage detection Stable disease 4mths 18mths CVactreatment demonstrates stabilization of CA125 initially for 4mths, then for further 18mths post further inje
Slide 14: CVac: Targeting Ovarian Cancer
CVac: Targeting Ovarian Cancer • Phase I and IIa trials indicate CVac could be strong candidate for treating ovarian cancer patients in remission & for other MUC-1 over-expressing tumors • Phase IIb trial (63 patients) for ovarian cancer patients nd after successful 1st or 2 line therapy has complet
Slide 15: Pivotal (CANVAS) Study Design
CVac: Pivotal (CANVAS) Study Design Potential maintenance treatment for epithelial ovarian, primary peritoneal or fallopian tube cancer in complete remission • CANVAS( CAN cer VAccine S tudy) is multinational, multi- centre, randomized, double-blinded, placebo-controlled – 800 patients randomized, d
Slide 16: Assessing Global Market Potential
CVac: Assessing Global Market Potential SIGNIFICANT MARKET OPPORTUNITY Multi-billion dollar ovarian cancer treatment vaccine market Global market size is estimated to be $3.6 billion First to market maintenance therapy has potential to achieve 10% of market in first year of launch 10% of market may
Slide 17: Anti-Cripto-1 Mab
Anti-Cripto-1 Mab 4 it en = i A, §. _ 17 ©) PRIMA BIOMED LTD Australian Cancer Treatment Company
Slide 18: Driving Differentiation with Science: Anti-Cripto-1 Mab
Driving Differentiation with Science: Anti-Cripto-1 Mab • Identification and development of a monoclonal antibody to Cripto-1 – Protein found in high levels on the surface of many tumors – Neutralizing the Cripto-1 protein may enable targeting of multiple tumor types (breast, colon, lung, stomach &
Slide 19: Oral HPV Vaccine
Oral HPV Vaccine 4 it en = i A, §. _ 19 ©) PRIMA BIOMED LTD Australian Cancer Treatment Company
Slide 20: Driving Differentiation with Science: Oral HPV Vaccine
Driving Differentiation with Science: Oral HPV Vaccine • Developing technology to enable oral administration of vaccines that are currently injected - Reformulate large, irregular particles into smaller consistent sizes allowing higher bioavailability of lower doses in an oral formulation • Lead tar
Slide 21: Financial Profile – Price & Capitalisation
Financial Profile – Price & Capitalisation Financial Profile ASX Code PRR (Australian Security) NASDAQ Code PBMD(ADR Lvl 2 30:1) Shares 1,065 million Price & Capitalization Share Price $0.24 (16/3/12) 2011 high $0.42 (4/11/11) Market Cap $255 million (as of March 2012) Cash Position $47.5 million (a
Slide 22: Prima BioMed: Strategically Positioned
Prima BioMed: Strategically Positioned • Develop and commercialize new therapies to address unmet medical needs primarily in oncology – CVac has potential to transform treatment of ovarian cancer in remission • Pivotal study has been designed to seek global registration in key markets including U.S.
Slide 23: The Cutting Edge in the Fight Against Cancer
The Cutting Edge in the Fight Against Cancer Investor Presentation April 2012 Martin Rogers Chief Executive Officer 23